CTLA4 and neoplasm: These findings thus suggest that despite the apparently dispensable role of ICOS in the efficacy of NDV-WT/anti-CTLA-4 combination, provision of the immunostimulatory ICOSL signal by NDV in the tumour could drive therapeutic enhancement, an effect that was dependent on an intact ICOS signalling pathway.